Brought to you by 
NuVasive buys Osiris's Osteocel business
May 2008
Executive Summary
Osiris Therapeutics (stem cell therapies for inflammatory, orthopedic, and cardiovascular indications) has sold NuVasive (minimally invasive devices for spine surgeries) its Osteocel biologics business, including a processing facility.
Deal Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Includes Contract
- Full Acquisition
- Includes Earnout
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NuVasive buys Osiris's Osteocel business
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice